Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 50.26% | 78.34% | -13.90% | -42.15% | 4.92% |
| Total Depreciation and Amortization | -2.18% | 0.41% | -15.03% | 6.07% | 1.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.72% | -78.33% | 9.59% | 129.05% | -290.54% |
| Change in Net Operating Assets | 39.83% | -1,878.63% | 518.64% | -99.06% | 374.24% |
| Cash from Operations | 119.36% | -24.65% | -7.84% | -27.68% | 41.45% |
| Capital Expenditure | -24.98% | -4.16% | 7.28% | -23.49% | 8.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 90.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.80% | 174.38% | -142.25% | 336.42% | 77.31% |
| Cash from Investing | -210.79% | 78.39% | -294.69% | 154.68% | 63.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 511.59% | -69.83% | -67.61% | 1,149.38% | 27.94% |
| Repurchase of Common Stock | 57.91% | -35.68% | 27.16% | -78.55% | 37.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.14% | 1.02% | -5.50% | -1.64% | 1.51% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 76.30% | -52.66% | -2.83% | -8.66% | 36.37% |
| Foreign Exchange rate Adjustments | 266.67% | 66.67% | -200.00% | 25.00% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 338.92% | -229.59% | -125.07% | 22.73% | 146.18% |